Long-Term Use of Contraceptive Depot Medroxyprogesterone Acetate in Young Women Impairs Arterial Endothelial Function Assessed by Cardiovascular Magnetic Resonance
暂无分享,去创建一个
D. Pennell | C. Hayward | P. Gatehouse | A. Elkington | C. Webb | A. Kubba | P. Collins | M. B. Sorensen | P. Ong | E. Asbury | Guang-Zhao Yang | M. B. Sørensen
[1] A. Wakatsuki,et al. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. , 2003, Circulation.
[2] M. Watkins,et al. Risk Stratification for Postoperative Cardiovascular Events via Noninvasive Assessment of Endothelial Function: A Prospective Study , 2002, Circulation.
[3] A. Wakatsuki,et al. Effect of Medroxyprogesterone Acetate on Endothelium-Dependent Vasodilation in Postmenopausal Women Receiving Estrogen , 2001, Circulation.
[4] C. Hayward,et al. Tamoxifen is not detrimental to endothelial function in postmenopausal women with breast cancer. , 2001, American heart journal.
[5] V. Rickert,et al. A Prospective, Controlled Study of the Effects of Hormonal Contraception on Bone Mineral Density , 2001, Obstetrics and gynecology.
[6] M. Sowers,et al. Magnitude and variability of sequential estradiol and progesterone concentrations in women using depot medroxyprogesterone acetate for contraception. , 2001, Fertility and sterility.
[7] A. Lusis,et al. Testosterone inhibits early atherogenesis by conversion to estradiol: Critical role of aromatase , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[8] K. Kugiyama,et al. Effect of medroxyprogesterone acetate plus estradiol on endothelium-dependent vasodilation in postmenopausal women. , 2001, The American journal of cardiology.
[9] A. Meier,et al. Depomedroxyprogesterone‐induced Hypoestrogenism and Changes in Vaginal Flora and Epithelium , 2000, Obstetrics and gynecology.
[10] D J Pennell,et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? , 2000, European heart journal.
[11] C. Delles,et al. Effects of oral contraceptives on vascular endothelium in premenopausal women. , 2000, American journal of obstetrics and gynecology.
[12] R. Cannon,et al. Oral L-arginine in patients with coronary artery disease on medical management. , 2000, Circulation.
[13] A M Zeiher,et al. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. , 2000, Circulation.
[14] S. Higano,et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. , 2000, Circulation.
[15] R. Karas,et al. The protective effects of estrogen on the cardiovascular system. , 2002, The New England journal of medicine.
[16] C. Hayward,et al. Effect of fat and carbohydrate consumption on endothelial function , 1999, The Lancet.
[17] R. Cannon,et al. Vascular effects of estrogen and vitamin E therapies in postmenopausal women. , 1999, Circulation.
[18] C. Webb,et al. Estrogen hits the surface , 1999, Nature Medicine.
[19] D. Horsfall,et al. Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells , 1999, Molecular and Cellular Endocrinology.
[20] A. Chang,et al. Prospective randomized study of the effect of "add-back" hormone replacement on vascular function during treatment with gonadotropin-releasing hormone agonists. , 1998, Circulation.
[21] P. Ganz,et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. , 1998, Circulation.
[22] P. Fletcher,et al. Reproducibility of brachial ultrasonography and flow-mediated dilatation (FMD) for assessing endothelial function. , 1997, Australian and New Zealand journal of medicine.
[23] J. Rösch,et al. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm , 1997, Nature Medicine.
[24] C. Stehouwer,et al. Modulation of endothelium-dependent, flow-mediated dilatation of the brachial artery by sex and menstrual cycle. , 1996, Circulation.
[25] S. Nakao,et al. Non-invasive detection of endothelial dysfunction with 30 MHz transducer , 1996, The Lancet.
[26] D. Mishell. Pharmacokinetics of depot medroxyprogesterone acetate contraception. , 1996, The Journal of reproductive medicine.
[27] M. Frederiksen. Depot medroxyprogesterone acetate contraception in women with medical problems. , 1996, The Journal of reproductive medicine.
[28] J. K. Lloyd,et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis , 1992, The Lancet.
[29] L. Enk,et al. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids. , 1992, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[30] I. Reid,et al. Bone density in women receiving depot medroxyprogesterone acetate for contraception. , 1991, BMJ.
[31] S. Moncada,et al. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor , 1987, Nature.
[32] R. Furchgott,et al. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine , 1980, Nature.